Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-FANS: Iloperidone Switching Strategies in Schizophrenia
NCT01207414Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iloperidone in schizophrenia (2 arms), sponsored by Novartis. Primary endpoint: Integrated Clinical Global Impression of Change at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01207414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207414.